patients predicting likelihood acquire alzheimer possibly providing diagnosis symptoms noticeable enabling prevention currently available amyloid positron emission tomography pet scans cerebrospinal fluid tests biomarkers enroll patients clinical trials directed specific target beta amyloid measure body responds treatment recently biogen anti beta amyloid monoclonal antibody ultimately biomarkers determine therapies effective individual tools available diseases including diabetes hypertension hyperlipidemia cancer heart disease instance serum cholesterol levels measured simply drawing blood needle stick long biomarker identify patients risk test affordable generally covered employers health insurance providers including medicare blood levels high drugs statins prescribed lower cholesterol risk heart disease doctors use cholesterol levels